Meeting
2011 ASCO Annual Meeting
Phase I trial erlotinib, gemcitabine, and the hedgehog inhibitor, GDC-0449.
Authors
S. R. Palmer
Mayo Clinic, Rochester, MN
S. R. Palmer , C. Erlichman , M. Fernandez-Zapico , Y. Qi , L. Almada , A. McCleary-Wheeler , M. J. Borad , J. R. Molina , A. Grothey , H. C. Pitot , A. Jatoi , D. W. Northfelt , R. R. McWilliams , S. H. Okuno , P. Haluska , G. P. Kim , G. Colon-Otero
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
Signal Transduction
Clinical Trial Registration Number
NCT00878163
Citation
J Clin Oncol 29: 2011 (suppl; abstr 3092)
Abstract #
3092
Poster Bd #
18A
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
Phase I study of definitive chemoradiation with gemcitabine and the WEE1 inhibitor AZD1775 in unresectable pancreatic cancer.
First Author: Kyle Clifford Cuneo
Poster
2017 Gastrointestinal Cancers Symposium
Phase I/IB multicenter study of afatinib in combination with capecitabine in patients (pts) with refractory solid tumors and pancreatico-biliary cancers.
First Author: Amy E. Chang
Poster
2016 Gastrointestinal Cancers Symposium
A phase I trial of cabozantinib (XL184) and gemcitabine in advanced pancreatic cancer.
First Author: David Bing Zhen
Poster
2016 Gastrointestinal Cancers Symposium
Phase I study of veliparib with gemcitabine and radiation therapy in patients with borderline resectable and locally advanced unresectable pancreatic cancer.
First Author: Richard Tuli